drugset
drugset / Trial / NCT01500018

Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214

NCT01500018 ↗

Phase 1 Withdrawn AstraZeneca
RandomizedCrossoverTriple-blindBasic science

Summary

This is a single dose, crossover study to assess the abuse potential of TC-5214 compared to placebo, ketamine, and phentermine in healthy recreational polydrug users.

Timeline

Start
2012-01
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 100 mg Oral
Subject Phentermine Small molecule 45 mg Oral
Subject Phentermine Small molecule 90 mg Oral
Subject dexmecamylamine Other / unclassified 2 mg Oral
Subject dexmecamylamine Other / unclassified 8 mg Oral
Subject dexmecamylamine Other / unclassified 16 mg Oral

Indications

substance abuse